KURA

Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

Retrieved on: 
Tuesday, March 14, 2023
Cancer, AACR, KURA, Annual general meeting, Abstract, SAN, Session, FTI, FDA, Investigational New Drug, American Association for Cancer Research, Kura, Pharmaceutical industry

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando from April 14-19, 2023.

Key Points: 
  • SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando from April 14-19, 2023.
  • “We look forward to presenting preclinical data supporting the combination of farnesyl transferase inhibitors (FTIs) with KRASG12C inhibitors and tyrosine kinase inhibitors at this year’s AACR Annual Meeting,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • “These data add to the emerging body of evidence supporting the potential to use FTIs as combination agents to prevent or delay emergence of resistance to certain classes of targeted therapy.
  • Copies of the presentations will be available on Kura's website at https://kuraoncology.com/pipeline/#posters_and_presentations following presentation at the meeting.

Kura Oncology to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 1, 2023
Corporation, Cancer, SAN, KURA, Conference, Pharmaceutical industry

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

Key Points: 
  • SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:
    A “Leukemia Corporate Panel” discussion at the Cowen Health Care Conference in Boston at 12:50 p.m.
  • ET / 9:50 a.m. PT on March 8, 2023;
    A fireside chat at the Cowen Health Care Conference at 2:50 p.m.
  • ET / 11:50 a.m. PT on March 8, 2023; and
    A fireside chat at the Barclays Global Healthcare Conference in Miami at 2:35 p.m.
  • Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com , with archived replays available following the events.

KURA ONE, Compact Cans of Japanese Sake Featuring Brands From Award-winning Sake Breweries in Japan and Overseas, Is Now Available as a Subscription Service Delivered Worldwide!

Retrieved on: 
Tuesday, February 28, 2023
Restaurant, Bar, Home Goods, Luxury, Wine & Spirits, Retail, Tue, B2B, Multimedia, Tax, Temperature, Shigaraki, Shiga, KURA, Glass, Beer

KURA ONE meticulously selects sake from brands of award-winning sake breweries in Japan and overseas and repackages them in compact and easy-to-handle 180ml/196g aluminum cans, while maintaining the quality of the sake.

Key Points: 
  • KURA ONE meticulously selects sake from brands of award-winning sake breweries in Japan and overseas and repackages them in compact and easy-to-handle 180ml/196g aluminum cans, while maintaining the quality of the sake.
  • Subscription”: 3-4 cans of brands from domestic and international award-winning sake breweries delivered each month.
  • "KURA ONE Glass Sake Cup Box": includes 4 types of sake glasses of Kimoto Glassware used in famous restaurants, and 2 cans of KURA ONE.
  • "KURA ONE Temperature Sensitive Sake Cups Box": includes 2 mysterious sake vessels whose cherry blossom color changes depending on the sake temperature, and 2 cans of KURA ONE.

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Safety, Bristol Myers Squibb, ID, FTI, FLT3, Cancer, QT interval, III, Farnesol, EGFR, IDH, Disease, EORTC, Organization, Research, IND, Webcast, FDA, Investment, Patient, Element, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ASH, KRAS, PI3, CRH, Azacitidine, Renal cell carcinoma, Kura, KURA, Society, AML, HNSCC, Head, CR, PIK3CA, Daunorubicin, Data, Food, G&A, Lung cancer, Acute myeloid leukemia, Pharmaceutical industry, Video game

ET –

Key Points: 
  • ET –
    SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2022 financial results and provided a corporate update.
  • Research and development expenses for the fourth quarter of 2022 were $22.7 million, compared to $21.0 million for the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $12.5 million, compared to $12.1 million for the fourth quarter of 2021.
  • ET / 1:30 p.m. PT today, February 23, 2023, to discuss the financial results for the fourth quarter and full year 2022 and to provide a corporate update.

Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 16, 2023
SAN, Webcast, KURA, Cancer, Pharmaceutical industry, Internet service provider

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023.

Key Points: 
  • SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023.
  • Kura’s management will host a webcast and conference call at 4:30 p.m.
  • ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
  • A replay of the webcast will be available online from the investor relations section of the company website at www.kuraoncology.com .

Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Retrieved on: 
Thursday, February 9, 2023
AML, KURA, Food, Safety, CRH, Menin, Cancer, CR, Kura, Patient, Acute leukemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Acute myeloid leukemia, Pharmaceutical industry

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in its KOMET-001 Phase 2 registration-directed trial of ziftomenib, the Company’s novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).

Key Points: 
  • – Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe –
    SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in its KOMET-001 Phase 2 registration-directed trial of ziftomenib, the Company’s novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
  • “Dosing the first patients in our registration-directed trial of ziftomenib marks a significant milestone for our menin inhibitor program,” said Troy Wilson, Ph.D., J.D., President & Chief Executive Officer of Kura Oncology.
  • “Building on the strength of our Phase 1 data, we remain committed to our mission to realize the full potential of ziftomenib as an important treatment option to patients with acute leukemia.
  • For more information regarding the KOMET-001 trial, please visit www.clinicaltrials.gov (identifier: NCT04067336 ).

Kura Oncology to Participate in SVB Securities Global Biopharma Conference

Retrieved on: 
Tuesday, February 7, 2023
Conference, KURA, Cancer, SAN, Pharmaceutical industry, Broadcasting

SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the virtual SVB Securities Global Biopharma Conference.

Key Points: 
  • SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the virtual SVB Securities Global Biopharma Conference.
  • Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 5:00 p.m.
  • ET / 2:00 p.m. PT on February 14, 2023.
  • A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com , with an archived replay available following the event.

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

Retrieved on: 
Tuesday, January 24, 2023
KURA, Food, Safety, IND, Cancer, Pharmacokinetics, Kura, Patient, SAN, FTI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Investigational New Drug, Pharmaceutical industry

SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors.

Key Points: 
  • SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors.
  • The Company intends to evaluate safety, tolerability and preliminary antitumor activity of KO-2806 in a Phase 1 first-in-human study as a monotherapy and in combination with other targeted therapies.
  • "Over the past several years, we have pioneered the development of farnesyl transferase inhibitors as combination agents to prevent or delay emergence of resistance to certain classes of targeted therapy.
  • Following completion of the dose escalation as a monotherapy, Kura plans to evaluate KO-2806 in dose escalation combination cohorts in advanced solid tumors.

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Mixed-phenotype acute leukemia, Neoplasm, Incidence, Security (finance), KURA, DNMT3A, Acute leukemia, ASH, FLT3, AML, QT interval, Toxicity, Research, Food, FDA, Safety, Cancer, Bone marrow, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRD, Duke Cancer Institute, IDH, Society, FTI, Therapy, Breakthrough therapy, CRH, KMT2D, News, HRAS, Venetoclax, Element, Disease, Patient, DS, NPM1, CT, Prognosis, Optimus, CR, Survival, Orphan, IND, HNSCC, Risk, Postcholecystectomy syndrome, Pharmaceutical industry, KMT2A

SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical data from KOMET-001, a Phase 1/2 trial of the Company’s potent and selective menin inhibitor, ziftomenib, including an encouraging safety and tolerability profile and clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML).

Key Points: 
  • These data are being featured during an oral session today at the American Society of Hematology (ASH) Annual Meeting.
  • The patient entered the trial having progressed through seven prior lines of therapy and remains on ziftomenib after two years.
  • ET today, December 10, 2022, following the oral presentation of updated data from the KOMET-001 clinical trial at the ASH Annual Meeting in New Orleans.
  • Ziftomenib, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) in patients with NPM1-mutant and KMT2A-rearranged AML.

Kura Oncology to Host Investor Event on December 10, 2022

Retrieved on: 
Thursday, December 1, 2022
HRAS, SAN, Breakthrough therapy, IND, Acute myeloid leukemia, Patient, KURA, Society, HNSCC, Webcast, Neoplasm, ASH, Cancer, FTI, CT, Kura, Pharmaceutical industry

The in-person investor event and live webcast will take place on Saturday, December 10, 2022, at 11:15 a.m. CT / 12:15 p.m.

Key Points: 
  • The in-person investor event and live webcast will take place on Saturday, December 10, 2022, at 11:15 a.m. CT / 12:15 p.m.
  • ET, following an oral presentation of updated data from the KOMET-001 trial at the American Society of Hematology (ASH) Annual Meeting in New Orleans.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Companys next-generation FTI, through IND-enabling studies.